Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 4/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244065 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL14605825 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL5435908 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL5429033 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL1414979 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL5748972 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL3330154 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL5747937 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL22418410 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL14052951 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-10800816-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-2827883-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10201586-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | disclosed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-7521566-B2 | Process for preparation of perindopril and salts thereof | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-7521566-B2 | Process for preparation of perindopril and salts thereof | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-7456296-B2 | Method for preparation of crystalline perindopril erbumine | LUPIN LTD (IN) | 2008-11-25 | — | — | US | disclosed |
| EP-1603558-B1 | PROCESS FOR PREPARATION OF PERINDOPRIL AND SALTS THEREOF | SERVIER S A LAB (FR) | 2008-05-21 | — | — | EP | disclosed |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | LUPIN LTD. (IN) | 2007-06-28 | — | — | US | disclosed |
| EP-1615885-A1 | B -FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | BARVIAN NICOLE C (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2004092132-A1 | [B]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | CYP2D6 3856/4885LMNA 1445/4885BLM 4480/4885 |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | CYP2D6 3769/4885LMNA 1505/4885BLM 4444/4885 |
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | PRAP1, PRR12, PPIB | CYP2D6 4004/4885LMNA 1576/4885BLM 3792/4885 |
| US-10201586-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | CYP2D6 3870/4885LMNA 1466/4885BLM 4503/4885 |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | REN, AGTR2, AGTR1 | CYP2D6 40/4885LMNA 1430/4885BLM 2602/4885 |
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | CYP2D6 3870/4885LMNA 1466/4885BLM 4503/4885 |
| US-10800816-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F13B | CYP2D6 3769/4885LMNA 1505/4885BLM 4444/4885 |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | CYP2D6 3870/4885LMNA 1466/4885BLM 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.